Meliora Therapeutics is developing a proprietary prediction atlas - called AnchorOmics - to elucidate drug mechanisms and their impact on cancer biology. The "unit" AnchorOmics is a proprietary "molecular fingerprint". This fingerprint captures the impact of a therapeutic agent on the transcriptome, methylome, proteome, morphological state, and more of cells. Using advanced machine learning techniques, Meliora generates each perturbation’s fingerprint and locates that fingerprint in their atlas, thus mapping an anti-cancer drug’s mechanisms of action.

<p>Meliora Therapeutics is developing a proprietary prediction atlas - called AnchorOmics - to elucidate drug mechanisms and their impact on cancer biology. The &quot;unit&quot; AnchorOmics is a proprietary &quot;molecular fingerprint&quot;. This fingerprint captures the impact of a therapeutic agent on the transcriptome, methylome, proteome, morphological state, and more of cells. Using advanced machine learning techniques, Meliora generates each perturbation’s fingerprint and locates that fingerprint in their atlas, thus mapping an anti-cancer drug’s mechanisms of action.</p>


Meliora Therapeutics

Founded: 2021
Location: San Francisco, CA
Employee range: 1-50
Clinical stage: RD
Therapy area: Oncology
Drug types: ONC
Lead product: Undisclosed
Funding: 10-100M

About:

Jobs: